Author:
Wu Jingcheng,Li Jiaoyang,Chen Shuqing,Zhou Zhan
Reference26 articles.
1. Lee CH, Yelensky R, Jooss K, Chan TA (2018) Update on tumor neoantigens and their utility: why it is good to be different. Trends Immunol 39:536–548
2. Lu YC, Robbins PF (2016) Cancer immunotherapy targeting neoantigens. Semin Immunol 28:22–27
3. Snyder A, Makarov V, Merghoub T et al (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189–2199
4. Rizvi NA, Hellmann MD, Snyder A et al (2016) Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 80- ) 348:124–129
5. Riaz N, Havel JJ, Makarov V et al (2017) Tumor and microenvironment evolution during immunotherapy with Nivolumab. Cell 171:934–949.e15